how did they dropped their cash from 1.3 bil to 850 mil with positive earnings for the pass 4 quarters? Shouldn't someone look into their reports?
OK, I am looking at insider ownership, Alfred Mann owns over 1 mil, Hakan over 1 mil shares, and the rest of execs are about 300k shares. There are 400 mil shares total. HOw is it that insiders own 47% of the shares? If the top five execs total shares add up only to 3 mil shares, this is less than 1% of total shares. How did yahoo get 47%? What am I missing here?
New to Mnkd. thanks in advance for the explanation.
there is always a strong demand for oil; we send off our troops and they give up our lives to establish low price gasoline. This will bounce with a vengence.
the new CEO will find a way to make the numbers look profittable. Write offs done with old CFO, all behind us.
Oversold area here; shorts will have to cover soon.
exactly! even with write offs, last quarter loss was only $5 mil but revenue was approx $100 mil. Cut back on expenses, new watches, msft going mobil, fudge a few numbers with new CFO and we will have a profittable quarter
Market cap is north of $1 bil, Intel may buy it out for scrap parts.
Is the natural resource of oil increasing?
NO, it's depleting..
Will we run out of oil in the future?
Yes, it's just a mater of time.
IT WILL GO BACK UP, I BET MY LEFT BALL ON IT!
any selling below 30 is just plain stupid.
There is a reason for this slow launch; it was not intended to have massive demand. For one, manufacturing isn't capable of handling the demand and second is that SNY wants a full buyout. They don't want Afrezza to get too hot which could lead to competitors making bigger offers. SNY stated that they needed higher samples than expected; this suggests great interest but will the patients convert to perscription? How long does each sample last? This is the expected time from sample to script conversion, plus 1-2 weeks for scheduling appointment and getting Afrezza.
I am a very shrewd investor; I have eyed mnkd since FDA approval and I think the reward is the sky and risk is minimal at this range. I may have been lucky to have waited this long without the price trading higher. GLTA longs.
i wouldn't be too arrogant if I was to hold a short position. Be prepared to wake up to a buyout price; that is the short's biggest fear.
Buyout price: how much is Afrezza? + Technosphere? + inhaler?
in the event they can't get patients to try samples or scripts, then they can still bail without a huge commitment. If they can determine that patients like the samples and convert to perscriptions, it will secretly become a buyout without having to have huge sells, because they know that once they advertise they can generate a floodgate of interest in Afrezza.
i am guessing the appointment may be just to get the pft done but it can also be done immediately after scripts, 1-2 weeks after isn't going to change pft.
Sell mnkd shares ONLY after full advertisement campaign and failure, or sell them in a few years in triple digits area. Doctors are generally honest people; they would not boast about drugs that do not have the claims that they boast about. The reviews from some of these docs who are users of Afrezza are indicative of a blockbuster status.
week 1: only patients who knew about Afrezza prelaunch would have Afrezza.
Week 2: ONLY those docs who knew about Afrezza prelauch can write scripts for their patients.
week3: Initial drug reps teaching docs about Afrezza and setting up dinner presentations
week4: First drug rep dinner on Afrezza
week5: Second drug rep dinner on Afrezza.
Hockey stick pattern
how long does each sample pack last? The conversion from samplers to users will be a wealth of information for SNY to secretly buyout mnkd without causing a stir or bidding war.
that lasts 10 days to 2 weeks. Hence if they started giving those out week 2-3 to familiarize docs, we should start seeing perscriptions starting now.
then I told them I wanted afrezza, and they said they couldn't issue any script. What the heck? 6 weeks out and none of these guys have access to Afrezza. What kind of launch is this?